<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Dortet, Laurent</dc:creator>
  <dc:creator>Girlich, Delphine</dc:creator>
  <dc:creator>Virlouvet, Anne-Laure</dc:creator>
  <dc:creator>Poirel, Laurent</dc:creator>
  <dc:creator>Nordmann, Patrice</dc:creator>
  <dc:creator>Iorga, Bogdan I.</dc:creator>
  <dc:creator>Naas, Thierry</dc:creator>
  <dc:date>2017-01-03</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The metallo-β-lactamase NDM-1 is among the most worrisome resistance  determinants and is spreading worldwide among Gram-negative bacilli. A bleomycin  resistance gene, ble&lt;sub&gt;MBL&lt;/sub&gt;, downstream of the bla&lt;sub&gt;NDM-1&lt;/sub&gt;  gene has been associated with resistance almost systematically. Here, we  characterized the corresponding protein, BRP&lt;sub&gt;MBL&lt;/sub&gt;, conferring resistance  to bleomycin, an antitumoral glycopeptide molecule. We have determined whether the  expression of the bla&lt;sub&gt;NDM-1&lt;/sub&gt;-ble&lt;sub&gt;MBL&lt;/sub&gt; operon is inducible in  the presence of carbapenems and/or bleomycin-like molecules using quantitative  reverse transcription-PCR (qRT-PCR), determination of imipenem and zeocin MICs,  and carbapenemase-specific activity assays. We showed that the bla&lt;sub&gt;NDM- 1&lt;/sub&gt;-ble&lt;sub&gt;MBL&lt;/sub&gt; operon is constitutively expressed. Using electrophoretic  mobility shift and DNA protection assays performed with purified glutathione S- transferase (GST)-BRP&lt;sub&gt;MBL&lt;/sub&gt;, we demonstrated that  BRP&lt;sub&gt;MBL&lt;/sub&gt; is able to bind and sequester bleomycin-like molecules, thus  preventing bleomycin-dependent DNA degradation. In silico modeling confirmed that  the mechanism of action required the dimerization of the BRP&lt;sub&gt;MBL&lt;/sub&gt; protein  in order to sequester bleomycin and prevent DNA damage. BRP&lt;sub&gt;MBL&lt;/sub&gt; acts  specifically on bleomycin-like molecules since cloning and expression of  ble&lt;sub&gt;MBL&lt;/sub&gt; in Staphyloccoccus aureus did not confer cross-resistance to  any other antimicrobial glycopeptides such as vancomycin and teicoplanin.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/305288</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305288/files/nor_cbb.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/305288/files/nor_ceg_sm.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1128/AAC.02413-16</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Antimicrobial Agents and Chemotherapy. - 2017, vol. 61, no. 3, p. e02413-16</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Characterization of BRP&lt;sub&gt;MBL&lt;/sub&gt; the bleomycin resistance protein associated with the carbapenemase NDM</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
